Activating EGFR-mutations occur in 10–35% of NSCLC cases, almost all of the lung adenocarcinoma (LAC) type, with significant ethnic variations (8–15% of LACs occur in Caucasians and 30–60% in East Asian populations) and a higher incidence among females, non-smokers, and patients younger than NSCLC patients with wild-type (wt) EGFR [1,2,3,4,5,6,7]. This evidence concerns the gene EGFR and lung adenocarcinoma.